Monitoring Antitumor Efficacy of Rapamycin in Kaposi Sarcoma

American Journal of Kidney Diseases

Volumn 49, Issue 3, 2007, Pages 462-470

  Di Paolo, Salvatore ^a   Teutonico, Annalisa ^a   Ranieri, Elena ^b   Gesualdo, Loreto ^c   Schena, Paolo F ^a  

^a UNIVERSITY OF BARI   (Italy)

^b Department of Biomedical Sciences ^*  (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

Author keywords

AKT; Kaposi sarcoma; P70 S6 kinase; rapamycin sensitivity; surrogate molecular markers

Indexed keywords

CYCLOSPORIN A; MAMMALIAN TARGET OF RAPAMYCIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; KAPOSI SARCOMA; KIDNEY TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION;

ADULT; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MONOCYTES; PATIENT SELECTION; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SARCOMA, KAPOSI; SIGNAL TRANSDUCTION; SIROLIMUS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 33847314632     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2006.11.037     Document Type: Article

References (45)

1. Andres A. Cancer incidence after immunosuppressive treatment following kidney transplantation. Crit Rev Oncol Hematol 56 (2005) 71-85
2. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transplant 1 (1998) 147-158
3. Kasiske B.L., Snyder J.J., Gilbertson D.T., and Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 4 (2004) 905-913
4. Campistol J.M., Eris J., Oberbauer R., et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 17 (2006) 581-589
5. Law B.K. Rapamycin: An anti-cancer immunosuppressant?. Crit Rev Oncol Hematol 56 (2005) 47-60
6. Morgensztern D., and McLeod H.L. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16 (2005) 797-803
7. Guertin D.A., and Sabatini D.M. An expanding role for mTOR in cancer. Trends Mol Med 11 (2005) 353-361
8. Stallone G., Schena A., Infante B., et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352 (2005) 1317-1323
9. Osaki M., Oshimura M., and Ito H. PI3K-Akt pathway: Its functions and alterations in human cancer. Apoptosis 9 (2004) 667-676
10. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., and Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4 (2005) 988-1004
11. Ruggero D., and Sonenberg N. The Akt of translational control. Oncogene 24 (2005) 7426-7434
12. Thompson J.E., and Thompson C.B. Putting the rap on Akt. J Clin Oncol 22 (2004) 4217-4226
13. Bais C., Van Geelen A., Eroles P., et al. Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/KDR. Cancer Cell 3 (2003) 131-143
14. Sodhi A., Montaner S., Patel V., et al. Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. Proc Natl Acad Sci U S A 101 (2004) 4821-4826
15. Noh W.C., Mondesire W.H., Peng J., et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10 (2004) 1013-1023
16. Peralba J.M., DeGraffenried L., Friedrichs W., et al. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 9 (2003) 2887-2892
17. Boulay A., Zumstein-Mecker S., Stephan C., et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64 (2004) 252-261
18. Teutonico A., Schena F.P., and Di Paolo S. Glucose metabolism in renal transplant recipients. The effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 16 (2005) 3128-3135
19. Cattaneo D., Perico N., and Gaspari F. Assessment of sirolimus concentrations in whole blood by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 774 (2002) 187-194
20. Di Paolo S., Teutonico A., Leogrande D., Capobianco C., and Schena F.P. Chronic inhibition of mTOR signaling down-regulates IRS-1/2 and AKT activation: A crossroad between cancer and diabetes?. J Am Soc Nephrol 17 (2006) 2236-2244
21. Ensoli B., Sgadari C., Barillari G., Sirianni M.C., Stürzl M., and Monini P. Biology of Kaposi's sarcoma. Eur J Cancer 37 (2001) 1251-1269
22. Cesarman E., Mesri E.A., and Gershengorn M.C. Viral G protein-coupled receptor and Kaposi's sarcoma: A model of paracrine neoplasia?. J Exp Med 191 (2000) 417-422
23. Ascherl G., Sgadari C., Bugarini R., et al. Serum concentrations of fibroblast growth factor 2 are increased in HIV type 1-infected patients and inversely related to survival probability. AIDS Res Hum Retroviruses 17 (2001) 1035-1039
24. Wang H.W., Trotter M.W., Lagos D., et al. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet 36 (2004) 687-693
25. Akula S.M., Ford P.W., Whitman A.G., et al. B-Raf-dependent expression of vascular endothelial growth factor-A in Kaposi sarcoma-associated herpesvirus-infected human B cells. Blood 105 (2005) 4516-4522
26. Heijnen C.J., Rouppe van der Voort C., van de Pol M., and Kavelaars A. Cytokines regulate alpha(1)-adrenergic receptor mRNA expression in human monocytic cells and endothelial cells. J Neuroimmunol 125 (2002) 66-72
27. Ballou L.M., Cross M.E., Huang S., McReynolds E.M., Zhang B.X., and Lin R.Z. Differential regulation of the phosphatidylinositol 3-kinase/Akt and p70 S6 kinase pathways by the alpha(1A)-adrenergic receptor in rat-1 fibroblasts. J Biol Chem 275 (2000) 4803-4809
28. Chang M., Brown H.J., Collado-Hidalgo A., et al. Beta-Adrenoreceptors reactivate Kaposi's sarcoma-associated herpesvirus lytic replication via PKA-dependent control of viral RTA. J Virol 79 (2005) 13538-13547
29. Harrington L.S., Findlay G.M., and Lamb R.F. Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem Sci 30 (2005) 35-42
30. Shen W.H., Jackson S.T., Broussard S.R., et al. IL-1beta suppresses prolonged Akt activation and expression of E2F-1 and cyclin A in breast cancer cells. J Immunol 172 (2004) 7272-7281
31. Awale S., Lu J., Kalauni S.K., et al. Identification of arctigenin as an antitumor agent having the ability to eliminate the tolerance of cancer cells to nutrient starvation. Cancer Res 66 (2006) 1751-1757
32. Takeuchi H., Kondo Y., Fujiwara K., et al. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res 65 (2005) 3336-3346
33. Wendel H.G., De Stanchina E., Fridman J.S., et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428 (2004) 332-337
34. Huang S., Bjornsti M.A., and Houghton P.J. Rapamycins: Mechanism of action and cellular resistance. Cancer Biol Ther 2 (2003) 222-232
35. Neri L.M., Borgatti P., Tazzari P.L., et al. The phosphoinositide 3-kinase/AKT1 pathway involvement in drug and all-trans-retinoic acid resistance of leukemia cells. Mol Cancer Res 1 (2003) 234-246
36. Xu G., Zhang W., Bertram P., Zheng X.F., and McLeod H. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol 24 (2004) 893-900
37. Vignot S., Faivre S., Aguirre D., and Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16 (2005) 525-537
38. Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (2004) 909-918
39. Li H.L., Davis W., and Pure E. Suboptimal cross-linking of antigen receptor induces Syk-dependent activation of p70S6 kinase through protein kinase C and phosphoinositol 3-kinase. J Biol Chem 274 (1999) 9812-9820
40. Miyakawa M., Tsushima T., Murakami H., Wakai K., Isozaki O., and Takano K. Increased expression of phosphorylated p70S6 kinase and Akt in papillary thyroid cancer tissues. Endocr J 50 (2003) 77-83
41. Nathan C.A., Amirghahari N., Abreo F., et al. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway. Clin Cancer Res 10 (2004) 5820-5827
42. van der Hage J.A., van den Broek L.J., Legrand C., et al. Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients. Br J Cancer 90 (2004) 1543-1550
43. Sahin F., Kannangai R., Adegbola O., Wang J., Su G., and Torbenson M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 10 (2004) 8421-8425
44. Lyzogubov V.V., Lytvyn D.I., Dudchenko T.M., et al. Immunohistochemical analysis of S6K1 and S6K2 expression in endometrial adenocarcinomas. Exp Oncol 26 (2004) 287-293
45. Amornphimoltham P., Patel V., Sodhi A., et al. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res 65 (2005) 9953-9961